Phio Pharmaceuticals Corp. PHIOW 深 沪
交易中 02-06 09:45:20 美东时间
0.0232
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0232
- 总市值 10.63万
- 52周最高 1.16
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.006
- 委 比 0.00%
- 总股本 458.09万
- 历史最高 1.16
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.006
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Phio Pharmaceuticals Data From Phase 1b Dose Escalation Clinical Study Shows 14 Participants To Be Pathologic Responders, Including 10 With 100% Clearance
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced
01-20 22:35
Phio Advances PH-762 With FDA-Backed Toxicology Study
Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On December 23, ...
2025-12-23 22:15
Phio Pharmaceuticals' Nonclinical Protocol For PH-762 Accepted By FDA; Toxicology Study Set To Begin In Q1 2026 Following Phase 1b Skin Cancer Results
Nonclinical protocol study design accepted by FDAStudy to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage
2025-12-23 21:47
Phio Pharmaceuticals Completes Enrollment In Phase 1b Trial Of PH-762 siRNA Cancer Therapy
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today
2025-11-26 00:33
Phio Pharma Q3 EPS $(0.44) Misses $(0.40) Estimate
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.40) by 10 percent. This is a 71.43 percent increase over losses of $(1.54) per share from the
2025-11-14 05:23
Phio Pharmaceuticals Exercises Warrants for $13.4 Million
Phio Pharmaceuticals ( ($PHIO) ) just unveiled an update. On November 3, 2025, ...
2025-11-07 05:38
Phio Pharma Secures $13.4M Through Warrant Exercises Covering 5.66M Shares, Including Reduced $2.05 Pricing On 4.65M Shares
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the
2025-11-04 03:02
Why Is Phio Pharmaceuticals Stock Soaring Today?
Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) are rising Monday after the company provided an update on an ongoing medical trial.
2025-11-04 02:25
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results
Phio Pharmaceuticals ( ($PHIO) ) just unveiled an announcement. On November 3, ...
2025-11-03 21:29
Phio Pharma Reports 100% Tumor Clearance In Final Dose Group Of Skin Cancer Trial
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today
2025-11-03 20:49
